

**Saskatchewan Health Authority - Saskatoon Area - ANTIBIOGRAM 2019**  
**Adult Outpatients - NON-Urinary Isolates**  
**January 1, 2019 - December 31, 2019**

**Outpatients – % Susceptible**

	# Isolates tested	Penicillin PO/IV	Ampicillin/Amoxicillin	Cloxacillin	Amoxicillin-Clavulanic acid	Piperacillin-Tazobactam	Cefazolin	Cefoxitin	Cefuroxime	Ceftriaxone	Ceftazidime	Meropenem	Ertapenem	Clindamycin	Azithromycin	Erythromycin	Tetracycline/Doxycycline	Ciprofloxacin	Moxifloxacin	Trimethoprim-Sulfamethoxazole	Gentamicin	Tobramycin	Vancomycin
<b>GRAM-NEGATIVE BACTERIA</b>																							
<i>Escherichia coli</i> <sup>1</sup> -	231	49		78	98	30	91			92	93	100	100					77		78	94	93	
<i>Enterobacter cloacae</i> <sup>2</sup> -	40	R		R	R	R	R			R	R	100	95					85		87	100	91	
<i>Haemophilus influenzae</i> -	40	63						90	100						98			100		70			
<i>Klebsiella pneumoniae</i> <sup>1</sup> -	60	R		97	100		83			97	97	100	100					85		85	98	96	
<i>Klebsiella oxytoca</i> †-	28	R		100	100		92			100	100	100	100					100		100	100	100	
<i>Pseudomonas aeruginosa</i> -	274				82						86	82						63			69	87	
<i>Proteus mirabilis</i> -	31	84		100	100		100			100	100	100	100					100		90	94	87	
<i>Serratia marcescens</i> <sup>2</sup> †-	21	R		R	R	R	R			R	R	100	100					95		100	100	100	

	# Isolates tested	Penicillin PO/IV	Ampicillin/Amoxicillin	Cloxacillin	Amoxicillin-Clavulanic acid	Piperacillin-Tazobactam	Cefazolin	Cefoxitin	Cefuroxime	Ceftriaxone	Ceftazidime	Meropenem	Ertapenem	Clindamycin	Azithromycin	Erythromycin	Tetracycline/Doxycycline	Ciprofloxacin	Moxifloxacin	Trimethoprim-Sulfamethoxazole	Gentamicin	Tobramycin	Vancomycin
<b>GRAM-POSITIVE BACTERIA</b>																							
<i>Staphylococcus aureus</i> , all																							
- methicillin-susceptible (MSSA) -	849			100			100							80		75	96	91	93	89			100
- methicillin-resistant (MRSA) -	509	R	R	R	R	R	R	R	R	R	R	R	R	70		38	99	51	51	95			100
<i>Staphylococcus epidermidis</i> -	98			R										57		35	92	54	54	52			100
<i>Staphylococcus lugdunensis</i> -	129			95				100						81		82	95	99	98	99			100
<i>Streptococcus pneumoniae</i> -	45	100							96	100		100		97		75			100				100
Group A Streptococcus †-	17	100								100				82		82							100
Group B Streptococcus	44	100								100				45		39							100
Group C/G Streptococcus	37	100								100				76		73							100
<i>Enterococcus faecalis</i>	131		100				R	R	R	R	R					R	R	92					100
<i>Enterococcus faecium</i> <sup>3</sup> †	23		R				R	R	R	R	R					R	61	R	R				87

R - intrinsically resistant

† Isolates containing less than 30 reported specimens should be interpreted using presented data ALONG WITH clinical judgement and/or input from infectious diseases service

<sup>1</sup> Overall extended spectrum beta-lactamase (ESBL) activity was seen in a weighted average of 4.3 % of samples of *E.coli*, *K.pneumoniae* and *P.mirabilis*

<sup>2</sup> These organisms may produce inducible beta-lactamase (AmpC) enzymes. Use of beta-lactams can result in clinical failure despite in vitro susceptibility

<sup>3</sup> VRE (vancomycin-resistant Enterococci) isolated from clinical specimens: *E.faecalis* 13% (N= 3)